BrainsWay (BWAY) is trading down at $12.23 (-2.16%), as of the latest quote. It operates in the Health Care sector.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.1M | $16.4M | $23.1M | $22.1M | $29.7M | $27.2M | $31.8M | $41.0M |
| Growth (year over year) | — | +47.1% | +40.9% | −4.5% | +34.5% | −8.4% | +17.0% | +29.0% |
| Gross profit | $8.55M | $12.8M | $18.0M | $17.0M | $23.1M | $20.0M | $23.5M | $30.6M |
| Gross margin | 76.7% | 78.1% | 77.8% | 77.1% | 77.7% | 73.8% | 73.9% | 74.6% |
| Operating income | −$6.61M | −$5.11M | −$8.48M | −$4.83M | −$5.00M | −$12.7M | −$4.96M | $1.39M |
| Operating margin | −59.3% | −31.2% | −36.7% | −21.9% | −16.9% | −46.7% | −15.6% | 3.4% |
| Net income | −$7.05M | −$6.48M | −$10.3M | −$5.38M | −$6.46M | −$13.3M | −$4.20M | $2.92M |
| Net margin | −63.3% | −39.5% | −44.7% | −24.4% | −21.8% | −49.1% | −13.2% | 7.1% |
| EPS (diluted) | −$0.48 | −$0.39 | −$0.50 | −$0.24 | −$0.21 | −$0.40 | −$0.13 | $0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $14.5M | $8.97M | $21.7M | $17.0M | $16.9M | $47.6M | $10.5M | $69.3M |
| Total assets | — | $23.6M | $38.7M | $34.0M | $75.7M | $64.5M | $63.0M | $94.3M |
| Total liabilities | — | $16.6M | $14.5M | $14.4M | $18.4M | $19.1M | $21.4M | $32.0M |
| Shareholders' equity | $12.7M | $6.95M | $24.2M | $19.6M | $57.3M | $45.4M | $41.6M | $62.3M |
| Cash flow | ||||||||
| Operating cash flow | −$3.47M | −$3.77M | −$7.24M | −$1.44M | $884.0K | −$9.76M | $1.28M | $10.3M |
| Capital expenditure | $985.0K | $1.97M | $3.31M | $2.47M | $2.24M | — | — | — |
| Free cash flow | −$4.45M | −$5.75M | −$10.6M | −$3.91M | −$1.35M | — | — | — |
| Q3 FY19Sep 2019 | Q4 FY19†Dec 2019 | Q3 FY20Sep 2020 | Q4 FY20†Dec 2020 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $6.29M | — | $7.07M |
| Growth (year over year) | — | — | — | +12.3% |
| Gross profit | — | $4.85M | — | $5.50M |
| Gross margin | — | 77.1% | — | 77.8% |
| Operating income | — | −$15.0M | — | −$9.25M |
| Operating margin | — | −237.8% | — | −130.9% |
| Net income | — | −$2.32M | — | −$406.0K |
| Net margin | — | −36.8% | — | −5.7% |
| EPS (diluted) | — | −$0.10 | — | −$0.02 |
| Balance sheet | ||||
| Cash and equivalents | $21.7M | $21.7M | $15.8M | $17.0M |
| Total assets | $38.7M | $38.7M | $34.4M | $34.0M |
| Total liabilities | $14.5M | $14.5M | $14.5M | $14.4M |
| Shareholders' equity | $24.2M | $24.2M | $19.9M | $19.6M |
| Cash flow | ||||
| Operating cash flow | — | −$1.23M | — | $1.64M |
| Capital expenditure | — | $338.0K | — | −$85.0K |
| Free cash flow | — | −$1.57M | — | $1.73M |
From BrainsWay's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning BrainsWay in our feed yet.